Lessons from toxicology: Developing a 21st-century paradigm for medical research

Environmental Health Perspectives

Volumn 123, Issue 11, 2015, Pages A268-A272

  Langley, Gill ^a   Austin, Christopher P ^b   Balapure, Anil K ^c   Birnbaum, Linda S ^d   Bucher, John R ^d   Fentem, Julia ^e   Fitzpatrick, Suzanne C ^f   Fowle, John R ^g   Kavlock, Robert J ^h   Kitano, Hiroaki ⁱ   Lidbury, Brett A ^j   Muotri, Alysson R ^k   Peng, Shuang Qing ^l   Sakharov, Dmitry ^m   Seidle, Troy ⁿ   Trez, Thales ^o   Tonevitsky, Alexander ^p   van de Stolpe, Anja ^q   Whelan, Maurice ^r   Willett, Catherine ^s  

^a Humane Society International   (United Kingdom)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e UNILEVER RESEARCH   (United Kingdom)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g Science to Inform LLC   (United States)

^h U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

ⁱ The Systems Biology Institute   (Japan)

^j Biology and Environment   (Australia)

^k RADY CHILDREN'S HOSPITAL   (United States)

^l BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^m Scientific Research Centre Bioclinicum   (Russian Federation)

ⁿ Humane Society International   (Canada)

^o FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

^p MEDICAL RADIOLOGICAL RESEARCH CENTER   (Russian Federation)

^q PHILIPS RESEARCH LABORATORIES   (Netherlands)

^r JOINT RESEARCH CENTRE   (Italy)

^s Humane Society of the United States   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT; DEMOGRAPHY; ENVIRONMENTAL HEALTH; ENVIRONMENTAL IMPACT ASSESSMENT; HEALTH CARE SURVEY; HUMAN; INFORMATION PROCESSING; MEDICAL RESEARCH; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; TOXICOLOGY; ANIMAL TESTING ALTERNATIVE; COMPUTER SIMULATION; DRUG DEVELOPMENT; GENOMICS; PROCEDURES; SYSTEMS BIOLOGY;

ANIMAL TESTING ALTERNATIVES; BIOMEDICAL RESEARCH; COMPUTER SIMULATION; DRUG DISCOVERY; GENOMICS; HUMANS; SYSTEMS BIOLOGY; TOXICOLOGY;

EID: 84946055501     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1510345     Document Type: Article

References (41)

1. Andreev VP, Petyuk VA, Brewer HM, Karpievitch YV, Xie F, Clarke J, et al. 2012. Label-free quantitative LC-MS proteomics of Alzheimer’s disease and normally aged human brains. J Proteome Res 11(6):3053–3067; doi: 10.1021/pr3001546.
2. Beach TG. 2013. Alzheimer’s disease and the “Valley Of Death”: not enough guidance from human brain tissue? J Alzheimers Dis 33(Suppl 1):S219–S1.
3. Bellin M, Marchetto MC, Gage FH, Mummery CL. 2012. Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol 13(11):713–726; doi: 10.1038/nrm1.
4. Benam KH, Dauth S, Hassell B, Herland A, Jain A, Jang KJ, et al. 2015. Engineered in vitro disease models. Annu Rev Pathol 10(1):195–262; doi: 10.1146/annurev-pathol-012414-1.
5. Birnbaum LS, Jung P. 2010. Evolution in environmental health: incorporating the infectious disease paradigm. Environ Health Perspect 118(8):A327–A328; doi: 10.1289/ehp.1.
6. Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D’Avanzo C, et al. 2014. A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature 515(7526):274–1.
7. Collins FS. 2011. Reengineering translational science: the time is right. Sci Transl Med 3(90):90cm17; doi: 10.1126/scitranslmed.1.
8. Collins FS, Varmus H. 2015. A new initiative on precision medicine. N Engl J Med 372(2):793–795; doi: 10.1056/NEJMp1.
9. Ghosh S, Matsuoka Y, Asai Y, Hsin KY, Kitano H. 2011. Software for systems biology: from tools to integrated platforms. Nat Rev Genet 12(12):821–832; doi: 10.1038/nrg1.
10. Gohlke JM, Thomas R, Zhang Y, Rosenstein MC, Davis AP, Murphy C, et al. 2009. Genetic and environmental pathways to complex diseases. BMC Syst Biol 3:46; doi: 10.1186/1752-0509-3-1.
11. Jimenez CR, Verheul HM. 2014. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications. Am Soc Clin Oncol Educ Book:e504–e510. Available: http://meetinglibrary.asco.org/content/11400504-144 [accessed 14 May 2015].
12. Kaitin KI, DiMasi JA. 2011. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther 89(2):183–188; doi: 10.1038/clpt.2010.1.
13. Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, et al. 2007. Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 124(1):26–1.
14. Langley GR. 2014. Considering a new paradigm for Alzheimer’s disease research. Drug Discov Today 19(8):1114–1.
15. Lango H, Weedon MN. 2008. What will whole genome searches for susceptibility genes for common complex disease offer to clinical practice? J Intern Med 263(1):16–1.
16. Ledford H. 2008. Translational research: the full cycle. Nature 453:843–845; doi: 10.1038/453843a
17. Lioy PJ, Rappaport SM. 2011. Exposure science and the exposome: an opportunity for coherence in the environmental health sciences. Environ Health Perspect 119:A466–A467; doi: 10.1289/ehp.1.
18. Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, et al. 2010. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143(4):527–1.
19. Mitne-Neto M, Machado-Costa M, Marchetto MC, Bengtson MH, Joazeiro CA, Tsuda H, et al. 2011. Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. Hum Mol Genet 20:3642–3652; doi: 10.1093/hmg/ddr284.
20. Muotri AR. 2015. The human model: changing focus on autism research. Biol Psychiatry; doi: 10.1016/j.biopsych.2015.03.012.
21. NIH (National Institutes of Health) Roadmap Epigenomics Consortium. 2015. Integrative analysis of 111 reference human epigenomes. Nature 518(7539):317–330; doi: 10.1038/nature14248.
22. NRC (National Research Council). 2007. Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC:National Academies Press. Available: http://dels.nas.edu/Report/Toxicity-Testing-Twenty-first/11970 [accessed 14 May 2015].
23. OECD (Organisation for Economic Co-operation and Development). 2012. The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins. OECD Series on Testing and Assessment No. 168. Part 1: Scientific Evidence. ENV/JM/MONO(2012)10/PART1. Paris:OECD. Available: www.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2012)10/part1&doclanguage=en [accessed 14 May 2015].
24. OECD. 2013. Guidance Document on Developing and Assessing Adverse Outcome Pathways. OECD Environment, Health and Safety Publications. Series on Testing and Assessment, No. 184. ENV/JM/MONO(2013)6. Paris:OECD. Available: www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2013)6&doclanguage=en [accessed 14 May 2015].
25. Pound P, Bracken MB. 2014. Is animal research sufficiently evidence based to be a cornerstone of biomedical research? BMJ 348:g3387; doi: 10.1136/bmj.g1.
26. Rosén C, Hansson O, Blennow K, Zetterberg HE. 2013. Fluid biomarkers in Alzheimer’s disease–– current concepts. Mol Neurodegener 8:20; doi: 10.1186/1750-1326-8-1.
27. Scannell JW, Blanckley A, Boldon H, Warrington B. 2012. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11:191–200; doi: 10.1038/nrd3681.
28. SCHER (Scientific Committee on Health and Environmental Risks), SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks), SCCS (Scientific Committee on Consumer Safety). 2013. Addressing the New Challenges for Risk Assessment, March 2013. Brussels:European Commission. Available: http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_131.pdf [accessed 14 May 2015].
29. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. 2013. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110:3507–3512; doi: 10.1073/pnas.1.
30. Shenderov BA, Midtvedt T. 2014. Epigenomic programming: a future way to health? Microb Ecol Health Dis 8:25; doi: 10.3402/mehd.v25.1.
31. Singh N, Nigam M, Ranjan V, Zaidi D, Garg VK, Sharma S, et al. 2011. Resveratrol as an adjunct therapy in cyclophosphamide-treated MCF-7 cells and breast tumor explants. Cancer Sci 102(5):1059–1067; doi: 10.1111/j.1349-7006.2011.01893.x.
32. Tonevitsky AG, Maltseva DV, Abbasi A, Samatov TR, Sakharov DA, Shkurnikov MU, et al. 2013. Dynamically regulated miRNA-mRNA networks revealed by exercise. BMC Physiol 13:9; doi: 10.1186/1472-6793-13-1.
33. Twine NA, Janitz K, Wilkins MR, Janitz M. 2011. Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer’s disease. PLoS One 21:6; doi: 10.1371/journal.pone.0016266
34. van de Stolpe A, den Toonder J. 2013. Workshop meeting report organs-on-chips: human disease models. Lab Chip 13(18):3449–3470.
35. van de Stolpe A, Kauffmann RH. 2015. Innovative human-specific investigational approaches to autoimmune disease. RSC Adv 5:18451-18463; doi: 10.1039/c4ra15794j.
36. van der Sijde MR, Ng A, Fu J. 2014. Systems genetics: from GWAS to disease pathways. Biochim Biophys Acta 1842(10):1903–1.
37. Vinken M, Landesmann B, Goumenou M, Vinken S, Shah I, Jaeschke H, et al. 2013. Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury. Toxicol Sci 136(1):97–1.
38. Weibrecht I, Lundin E, Kiflemariam S, Mignardi M, Grundberg I, Larsson C, et al. 2013. In situ detection of individual mRNA molecules and protein complexes or post-translational modifications using padlock probes combined with the in situ proximity ligation assay. Nat Protoc 8(2):355–1.
39. Willett C. 2014. Adverse outcome pathways: Development and use in toxicology. In: Encyclopedia of Toxicology, Vol. 1 (Wexler P, ed). 3rd ed. Waltham, Massachusetts:Academic Press, 95–1.
40. Zanella F, Lyon RC, Sheikh F. 2014. Modeling heart disease in a dish: from somatic cells to disease- relevant cardiomyocytes. Trends Cardiovasc Med 24(1):32–1.
41. Zerhouni EA. 2014. Turning the Titanic. Sci Transl Med 6(221):221ed2; doi: 10.1126/scitranslmed.3008294.